Weihong Ding

Fudan University — China

Medicine · Health Sciences

16h-index806citations31works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(11), Prostate Cancer Treatment and Research(10), Urinary and Genital Oncology Studies(6), Immune cells in cancer(5), Cancer, Lipids, and Metabolism(4)

Publications31 total

The landscape of genitourinary cancer vaccines: clinical advances and future opportunities
Journal of Advanced Research·2025Open Access
Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer
Biomedicines·2024· 1 citedOpen Access
CXCL3/TGF-β-mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistance
iScience·2024· 10 citedOpen Access
Synergistic PTEN Restoration and CXCR2 Depletion with a Bone-Targeting Lipid Nanocomposite Inhibits Drug-Resistant CRPC Metastasis to Bone
SSRN Electronic Journal·2024Open Access
Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics
British Journal of Pharmacology·2023· 22 cited
Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer
Molecular Pharmaceutics·2021· 42 cited
The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer
Frontiers in Oncology·2021· 15 citedOpen Access
Depression Induced by CUMS Leads to Bladder Cancer Development and Local Tumor Immunosuppression in Mice
Journal of Oncology·2021· 10 citedOpen Access
Increased Risk of Recurrence of Non-Muscle Invasive Bladder Cancer Associated With Psychological Distress: A Prospective Cohort Study
Psychiatry Investigation·2021· 5 citedOpen Access
Chronic Psychological Stress Attenuates the Efficacy of anti-PD-L1 Immunotherapy for Bladder Cancer in Immunocompetent Mice
Cancer Investigation·2021· 16 cited
An Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer
2021· 1 citedOpen Access
Chronic Unpredictable Mild Stress Accelerates the Growth of Bladder Cancer in a Xenograft Mouse Model
Psychology Research and Behavior Management·2020· 16 citedOpen Access
Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it
British Journal of Pharmacology·2020· 104 cited
Mechanisms of Enzalutamide Resistance in Castration-Resistant Prostate Cancer and Therapeutic Strategies to Overcome It
2020· 6 citedOpen Access
SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer
Theranostics·2020· 75 citedOpen Access
Association between three genetic variants in kallikrein 3 and prostate cancer risk
Bioscience Reports·2018· 17 citedOpen Access
EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification
Medicine·2018· 5 citedOpen Access
<b><i>NOS3</i></b> 895G>T and <b><i>CBR3</i></b> 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP
Chemotherapy·2018· 3 cited
A Cumulative Analysis of Current Evidence for Association between Expression of Epithelial-Mesenchymal Transition Markers and Clinicopathological Outcomes in Patients after Radical Prostatectomy.
PubMed·2018· 1 cited
Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells
Biochemical and Biophysical Research Communications·2017· 21 cited
page 1 of 2Next →

Frequent Co-authors

Ke Xu(18), Chuanyu Sun(14), Guowei Xia(14), Qiang Ding(12), Yuancheng Gou(9), Yuan Gao(6), Shijun Tong(6), Zhongqing Chen(6), Qidong Zhou(6), Jun Tan(5), Chuanyu Sun(5), Zhiyu Qian(5), Guangliang Jiang(5), Qingfeng Hu(4), Jiyuan Chen(3), Shen Gao(3), Weimin Cai(3), Yuanyuan Mi(3), Luyao Gong(3), Yeheng Peng(3)